Viral Vaccines Flashcards

1
Q

what is the herd immunity goal in Canada for measles?

A

95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how does immune memory impact protection following vaccination?

A

without vaccination: second exposure

  • if long incubation period: long enough for Ab response to mount
  • if short incubation period: too fast for an Ab response to mount

vaccination: second expsosure

  • life long protective Ab levels –> incubation time is practically irrelevent - Ab is already present
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

is the SARS-Cov2 vaccine effective?

A

saved an estimated 20 million lives during its first year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are some indirect benefits of the covid vaccine?

A

not having a vaccine yet –> interruptions in medical care –> many cancers not being diagnosed in a timely manner

vaccine = eases the healthcare system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are 6 common components of vaccines? describe each

A
  1. active ingredients: viral or bacterial Ags that directly stimulate the immune system but cannot cause disease
  2. adjuvants: aluminum salts in small quantities that help to boost the immune response to the vaccine
  3. abx: prevent contamination by bacteria during the vaccine manufacturing process
  4. stabilizers: sugar/gelatin keep the vaccine effective until it is administered to a patient
  5. preservatives: thimersol prevents dangerous bacterial or fungal contamination (only used for influenza vaccines)
  6. trace components: residual inactivating ingredients such as formaldehyde, and residual cell culture materia (present in small quantities that do not pose a safety concern)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are 6 approaches to viral vaccine development? what are 8 drug admin routes?

A

viral vaccine

  1. live attenuated
  2. whole inactivated
  3. VLPs
  4. recombinant viral vectors
  5. recombinant subunits
  6. DNA or RNA

drug admin routes

  • otic
  • nasal
  • rectal/vaginal
  • injections
  • ocular
  • oral
  • inhalational
  • topical/transdermal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what 6 factors will determine if the technology will “work” outside of the lab?

A
  1. scale-up speed
  2. admin route
  3. number of doses
  4. development speed
  5. storage temperature
  6. facility of production
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what disease was the first live attenuated vaccine used for?

A

smallpox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe the basic biology of measles morbillivirus (MeV). why target MeV?

A

biology

  • -ssRNA, linear, env
  • uses fusion protein to bind to SLAM to enter cells, buds out of cells

why target

  • R0 = 12-18
  • severe complication in children and adults: hospitalization, pneumonia, encephalitis, death, complications during pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how was the MMR vaccine developed, specifically the measles aspect? how did this affect the vaccine strain? what are some characterisitcs of the non-active part of the vaccine?

A
  • MeV tropism restricted to humans and primates using CD46 receptor
  • MeV was isolated from a patient and passaged in chicken embryo fibroblasts (CEFs) –> basis for vaccine
  • CEFs lack CD46 –> virus adapts to new host environment, hence becoming attenuated towards human cellular environment (most mutations on F and H proteins)
  • this results in attentuated MeV having a potentially higher tropism than WT, but less virulence
  • MMR is lyophilized = stable; must be stored at 4C; unadjuvanted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what was a whole inactivated vaccine first used against?

A

typhoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe the inactivated polio vaccine (salk vaccine)

A
  • inactivated (formalin) poliovirus strains of all three poliovirus types
  • cannot replicate, may need higher and/or more frequent doses, coupled to adjuvants to increase immune reactivity
  • requires 4C storage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is a major drawback of live attenuated vaccines?

A

possibility of reverting to WT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what was a VLP vaccine first used against?

A

HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how was the VLP vaccine for HPV developed? what are non-active components?

A
  • generated through yeast-based expression system of capsid L1 protein –> self-assembles into VLPs
  • vaccine requires 4C storage, uses aluminum as adjuvant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what was a recombinant subunit vaccine first used against?

A

anthrax

16
Q

Describe the mRNA vaccine for SARS CoV 2

A

lipid nanoparticle contains 4 types of lipids

  1. ionizable cationic lipids: promote self assembly and allows delivery of mRNA to the cytoplasm
  2. lipid-linked polyethylene glycol (PEG): increases half-life of formulations
  3. cholesterol: stabilizing agent
  4. phospholipids: structural support

mRNA coding for spike protein

  • uridine modified to pseudouridine for increased stability and decreased anti-RNA immunity
  • spike mRNA delivery into cells permites intracellular translocation and processing of spike Ag and loading onto MHC-I and secretion/uptake by APCs and loading onto MHC-II

vaccine is unadjuvanted and requires 4C storage

17
Q

describe the subunit vaccine for sars cov 2

A
  • matrix-M adjuvant is “proprietary” – made from saponins in soapbark tree
  • PS80 nanoparticle core consists of hydrocarbon tail (oleic acid) attatched to a sugar like molecule (sorbitan) to which are attatched short chains of ethylene oxide –> mimics a cell “membrane” that spike inserts into
  • required 4C storage
18
Q

what was a recombinant viral vector first used against?

A

ebola (rVSV-ZEBOV)

19
Q

describe the basic biology of ebola virus

A

-ssRNA, env

20
Q

describe the ebola vaccine - how it works, safety considerations and other non-active components

A

replace VSV glycoprotein with ebolavirus glycoprotein

  • VSV is a liver, replicating virus capable of infecting various ruminants causing blistering lesions in the mouth
  • can infect and cause mild flu symtpoms in humans
  • unadjuvanted, requires ulta cold storage (-60C t0 -80C)